Combination of exosome vaccines, lenvatinib, and anti-PD-1 eradicates tumor in autochthonous hepatocellular carcinoma mice.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 42492521.
- Also identified by DOI 10.1016/j.xcrm.2026.102933.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Unresectable hepatocellular carcinoma (HCC) demands more effective therapeutics to overcome its dismal prognosis. Dendritic cell (DC)-derived exosomes (DEXs) modified with CP05-anchored HCC-targeting peptide (P47-P), DC-recruiting and -activating high-mobility group nucleosome-binding protein 1 (HMGN1) (N1ND-N), and lymphotactin domains (XCL1-X) make DEX<sub>PNX</sub>. In situ antigen release by oral lenvatinib (LEN) with intravenous DEX<sub>PNX</sub> (DEX<sub>PNX</sub>/LEN) synergistically promotes intratumoral DC recruitment and activation. This enhances tumor neoantigen cross-presentation, de novo T cell responses, and durable immunological memory against rechallenge in orthotopic HCC mice. Furthermore, DEX<sub>PNX</sub>/LEN suppresses tumor growth and increases tumor-infiltrating CD8<sup>+</sup> T cells in diethyl-nitrosamine (DENA)-induced and non-alcoholic steatohepatitis-associated HCC mice. Crucially, combining DEX<sub>PNX</sub>/LEN with anti-PD-1 eradicates established tumor and boosts intratumoral CD8<sup>+</sup> effector T cell expansion in autochthonous HCC mice. Our study demonstrates a generalizable strategy to elicit personalized antitumor responses by leveraging DEX vaccines to activate tumoral DCs against LEN-released antigens, strengthened by anti-PD-1 blocking T cell exhaustion. This represents a clinically viable approach to improve HCC outcomes.